PepGen Inc. - PEPG STOCK NEWS

PepGen Inc. (NASDAQ: PEPG) announced promising exon skipping results from its product candidates PGN-EDO53, PGN-EDO45, and PGN-EDO44 for Duchenne muscular dystrophy (DMD). In non-human primates (NHPs), PGN-EDO53 achieved exon skipping levels of 36.4% after one dose and 57.2% after three doses, significantly outperforming the comparator PPMO molecule. Additionally, PGN-EDO45 and PGN-EDO44 demonstrated high exon skipping in human myoblasts, indicating potential for treating approximately 50% of DMD patients amenable to exon skipping. The results affirm PepGen's Enhanced Delivery Oligonucleotide platform's transformative potential.

PepGen Inc. (Nasdaq: PEPG) reported its Q3 2022 results, highlighting successful Phase 1 trial data for PGN-EDO51, indicating high levels of oligonucleotide delivery and exon skipping in DMD patients. With cash reserves of $195.8 million, R&D expenses rose to $16 million, which is significantly higher than last year's $5.7 million. The net loss increased to $18.6 million from $8.1 million year-over-year. Upcoming milestones include initiating Phase 2a trials for PGN-EDO51 and Phase 1/2 trials for PGN-EDODM1 in the first half of 2023.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, will present at Stifel’s 2022 Annual Healthcare Conference on November 15, 2022, at 9:45 A.M. ET in New York. The presentation aims to highlight PepGen's innovative oligonucleotide therapies for severe neuromuscular and neurological diseases. A live webcast will be accessible on PepGen’s website, with a replay available for 90 days. PepGen's Enhanced Delivery Oligonucleotide (EDO) platform focuses on improving therapeutic efficacy through advanced cell-penetrating peptides.

PepGen Inc. (Nasdaq: PEPG) presented new data at the 27th International Hybrid Annual Congress of the World Muscle Society regarding its Duchenne muscular dystrophy (DMD) program, focusing on its lead candidate, PGN-EDO51. The data showed significant exon skipping and dystrophin restoration in both non-human primates and mouse models. Highlights include up to 93.1% exon skipping in murine models with PGN-EDO23 and 78% exon skipping in non-human primates with PGN-EDO51. The technology aims to improve oligonucleotide delivery for treating severe neuromuscular diseases.

PepGen Inc. (Nasdaq: PEPG) announced positive results from its Phase 1 trial of PGN-EDO51 for Duchenne muscular dystrophy (DMD). The clinical study demonstrated high levels of oligonucleotide delivery and exon skipping, exceeding previous therapies. The trial's primary endpoint was met, showing PGN-EDO51 was well-tolerated with mild adverse events. PepGen plans to initiate a Phase 2a multiple ascending dose trial in DMD patients in the first half of 2023, bolstered by findings suggesting potential accumulation of therapeutic proteins with repeated dosing.

PepGen Inc. has appointed Habib Joseph Dable to its Board of Directors, bringing nearly 30 years of experience from his tenure as President and CEO of Acceleron Pharma. Dable's leadership was instrumental in Acceleron's growth, including its blockbuster launch in 2019. This transition occurs as PepGen advances its clinical programs for PGN-EDO51, targeting Duchenne muscular dystrophy. The Board expects Dable's expertise in neurology and biotechnology to enhance PepGen's strategic direction and innovation efforts in developing therapies for severe neuromuscular diseases.

PepGen Inc. reported its Q2 2022 financial results, highlighting a successful IPO that raised $122.9 million, enabling operations through mid-2025. The company initiated its Phase 1 clinical trial for PGN-EDO51, targeting Duchenne muscular dystrophy. With $218.8 million in cash, PepGen plans to release initial clinical findings by year's end and expects to file for an Investigational New Drug (IND) application for PGN-EDODM1 in early 2023. R&D expenses rose to $14.2 million, reflecting increased clinical and personnel costs, leading to a net loss of $17.3 million for the quarter.

PepGen Inc. announced the appointment of Caroline Godfrey, Ph.D., to its Scientific Advisory Board, marking a transition from her role as Senior Vice President of Discovery. Dr. Godfrey, a scientific co-founder of the company, played a crucial role in its establishment and early-stage research. The move aims to leverage her expertise as PepGen expands its operations in Boston and focuses on advancing oligonucleotide therapies for neuromuscular and neurological diseases. CEO James McArthur expressed confidence in her continued contributions to the company's mission.

PepGen Inc. reported strong growth as a clinical-stage biotechnology company, focusing on treating severe neuromuscular diseases. Following a successful IPO in May, raising $122.9 million, the company began a Phase 1 trial of PGN-EDO51 for Duchenne muscular dystrophy (DMD) in April 2022. As of March 31, 2022, PepGen had $118.9 million in cash, expected to fund operations until mid-2025. However, net losses reached $18.2 million for Q1 2022, highlighting significant research and administrative expenses as the company ramps up development.